Vir Biotechnology Inc (VIR)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.22 | 1.21 | 1.16 | 1.16 | 1.23 | 1.22 | 1.24 | 1.35 | 1.35 | 1.25 | 1.34 | 1.44 | 1.36 | 1.38 | 1.43 | 1.74 | 1.28 | 1.16 | 1.19 | 1.25 |
Based on the data provided for Vir Biotechnology Inc, the solvency ratios indicate a strong financial position with minimal debt levels relative to assets, capital, and equity.
1. Debt-to-assets ratio: Throughout the reported periods from March 31, 2020, to December 31, 2024, the debt-to-assets ratio remained consistently at 0.00, suggesting that the company's total debt was negligible in relation to its total assets. This implies that the company's assets were primarily financed through equity and retained earnings rather than debt.
2. Debt-to-capital ratio: Similarly, the debt-to-capital ratio also remained stable at 0.00 across all the periods analyzed. This indicates that the company did not rely heavily on debt to finance its operations and investments, resulting in a well-balanced capital structure.
3. Debt-to-equity ratio: The debt-to-equity ratio was consistently reported as 0.00, indicating that the company had no debt in relation to its equity over the entire period. This reaffirms the company's strong financial position and low financial risk.
4. Financial leverage ratio: The financial leverage ratio, which measures the extent of a company's financial leverage, showed a slight fluctuation over the periods but generally remained below 2. A ratio below 2 indicates a moderate level of financial risk and suggests that the company was not highly leveraged.
In conclusion, based on the solvency ratios analyzed, Vir Biotechnology Inc appears to have a robust financial health with low debt levels and a conservative financial structure. These ratios demonstrate the company's ability to meet its financial obligations and suggest a low risk of insolvency or financial distress in the foreseeable future.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | — | -2,385.12 | -2,259.42 | -2,592.86 | -1,433.38 | -70.18 | -16.55 | -8.54 | 20.88 | 51.33 | 62.82 | 4,018.71 | — | — | — | — | — | — | — | — |
The interest coverage ratio measures a company's ability to pay its interest expenses on outstanding debt. A higher ratio indicates a better ability to meet interest obligations. In the case of Vir Biotechnology Inc, the interest coverage ratio has fluctuated significantly over the reporting periods.
- The interest coverage was not available (indicated as "—") from March 2020 to December 2021, suggesting either the company did not have any interest expenses or there was insufficient operating income to cover the interest payments.
- From March 2022 to December 2024, the interest coverage ratios were negative, indicating that the company's operating income was not sufficient to cover its interest expenses. The declining trend in negative values suggests a worsening ability to meet interest obligations.
- Notably, the most recent reported interest coverage ratio for December 31, 2024, was not available, highlighting the inconsistent reporting of financial data or potentially significant fluctuations in financial performance.
Overall, the trend of negative interest coverage ratios for Vir Biotechnology Inc indicates a concerning financial position regarding its ability to cover interest payments with its operating income. Investors and stakeholders should closely monitor the company's financial health and management of debt obligations.